Biotest 988: A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human) Civacir in Orthotopic Liver Transplant Recipients

Grants and Contracts Details

StatusFinished
Effective start/end date6/20/136/30/17

Funding

  • Biotest Pharmaceuticals Corporation: $162,875.00